The UK and US have reached a significant bilateral deal that will keep no tariffs on British drug exports being sold in the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to increase spending on drugs through the NHS. This commitment secures that tariffs on these key products will be held at nothing for a duration of three years.
This deal is in response to previous statements to hike import taxes on branded drug products, with increases discussed up to one hundred percent.
"This deal between the Britain reinforces the worldwide climate for cutting-edge drugs and introduces much-needed equity to U.S.–U.K. drug exports," an announcement noted.
Economic Impact
Drugs constitute one of the the United Kingdom's most significant exports to the US, which is clearly the largest destination for major UK drugmakers.
Export figures show that in the one-year period leading up to last September, the UK exported medicines valued at £11.1bn to the US. This figure accounted for nearly one-fifth of British export trade in that period.
"This agreement safeguards employment, boosts capital expenditure and paves the way for the UK to become a worldwide center for medical research," a minister stated.
Detailed NHS Changes
The deal entails several notable pledges from the British government:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to raise total public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must return to the NHS to control costs will be capped at fifteen percent. Last year, repayments exceeded 20%.
Recent Tensions
The pact takes place against a ongoing dispute between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
These tensions were exacerbated by claims that US customers were charged several times more for the equivalent treatments than people in the UK and Europe.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while substantial expansions have been pledged toward US facilities.
One official publicly accepted that the NHS must spend more on treatments, noting that its budget allocation on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
